Difference between revisions of "Sullivan RJ, et al. Nat. Med. (2019) cited as Ref 641 in DOI: 10.1038/s41392-020-0110-5 (Q9904)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Added link to [sliswiki]: Sullivan RJ, et al. Nat. Med. (2019) cited as Ref 641 in DOI: 10.1038/s41392-020-0110-5, #quickstatements; #temporary_batch_1589988087154)
(‎Created claim: Page(s) (P105): 929-935, #quickstatements; #temporary_batch_1590074839150)
 
(7 intermediate revisions by the same user not shown)
Property / First Author string
 +
Sullivan RJ
Property / First Author string: Sullivan RJ / rank
 +
Normal rank
Property / DOI Identifier
 +
Property / DOI Identifier: 10.1038/s41591-019-0474-7 / rank
 +
Normal rank
Property / PubMed ID
 +
Property / PubMed ID: 31171876 / rank
 +
Normal rank
Property / Publication Date
 +
2019
Timestamp+2019-01-01T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 year
Before0
After0
Property / Publication Date: 2019 / rank
 +
Normal rank
Property / Published In Name String
 +
Nat. Med.
Property / Published In Name String: Nat. Med. / rank
 +
Normal rank
Property / Volume
 +
25
Property / Volume: 25 / rank
 +
Normal rank
Property / title
 +
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients (English)
Property / title: Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients (English) / rank
 +
Normal rank
Property / Page(s)
 +
929-935
Property / Page(s): 929-935 / rank
 +
Normal rank

Latest revision as of 15:47, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Sullivan RJ, et al. Nat. Med. (2019) cited as Ref 641 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Sullivan RJ
    0 references
    0 references
    2019
    0 references
    Nat. Med.
    0 references
    25
    0 references
    Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients (English)
    0 references
    929-935
    0 references